

MAY. 18. 2005 11:39AM

AVENTIS US PAT DEPT

MAY 18 2005

NO. 5338 P. 1

TO: US USPTO GENERAL

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:
IVD 1118 US DIV

Applicants:
DUCOUX, et al.

Serial No.
10/663,124

Filing Date:
September 16, 2003

Title of Invention:
Novel Piperidine Derivatives, Process for Obtaining Them and Pharmaceutical Compositions Containing Them

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703.872.9306, on
Date of Deposit: May 18, 2005

Printed Name of Person Signing Certificate Renee McGinnis

Signature Renee McGinnis

Total Number of Pages Sent: 5

Attorney: Julie Anne KNIGHT

Group Art Unit: 1625

Examiner: DESAI, Rita J.

TO: Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Statement Under 37 CFR 3.73(b)</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | <input checked="" type="checkbox"/> Other <u>Copy of Executed Assignment - 2 pages</u> |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

FUD-118
US DIV

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 11/30/2005. OMB 0851-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	10/663,124
Filing Date	September 16, 2003
First Named Inventor	DUCOUX, et al.
Art Unit	1625
Examiner Name	DESAI, Rita J.
Attorney Docket Number	IVD 1118 US DIV

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

005487

☐ Please change the correspondence address for the above-identified application to:

☒ The address associated with
Customer Number:

005487

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature

Name

Markus JACOBI

Date

27 avril 2005

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TUD M8
AUS DIV

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: SANOFI-SYNTHELABO INC.Application No./Patent No.: 10/663,124Filed/Issue Date: September 16, 2003Entitled: NOVEL PIPERIDINE DERIVATIVES, PROCESS FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSANOFI-SYNTHELABO INC.

(Name of Assignee)

a French corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Markus JACOBI

Printed or Typed Name

27 avril 2005

Date

Telephone Number

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DN IVD 1118/DM

JOINT ASSIGNMENT

For good and valuable consideration received, we, 1) DUCOUX Jean-Philippe, 2) EMONDS-ALT Xavier, 3) GUEULE Patrick, 4) PROIETTO Vincenzo residing at 1) 2, Allée des Romarins, FR-34980 COMBAILLAUX, 2) La Balajade, FR-34980 COMBAILLAUX, 3) 6 rue des Amandiers, FR-34820 TEYRAN, 4) 1 Cour du Merle, FR-34680 SAINT GEORGES D'ORQUES, respectively, have sold, assigned and transferred and by these presents do hereby sell, assign and transfer to Sanofi-Synthelabo, a société anonyme of France, having a place of business at 174 Avenue de France, 75013 Paris, FRANCE, and to its successors, assigns and legal representatives the entire right, title and interest in the United States and its territorial possessions and in any and all foreign countries in and to all of our inventions and any and all improvements thereof disclosed in an application for (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same which

[] is being executed on even date herewith.

[X] was filed on 8 February 2000 in the form of an International Application which designated the United States of America under number PCT/FR00/00284, and which entered the National Stage in the United States of America under serial number _____ on _____.

[] was filed on _____ in the United States of America under serial number _____.


and the entire right, title and interest in and to said United States patent application and any divisions, continuations and continuations-in-part of said application and any patent applications claiming subject matter common thereto or corresponding thereto filed in the United States and/or foreign countries including all rights to claim priority and in and to any and all Letters Patent which may be granted on said applications in the United States and its territorial possessions and in any and all foreign countries and in and to any and all reissues, re-examinations and extensions of such Letters Patent.

We hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment, and I authorize and request the Patent Office Officials in the United States and any and all foreign countries to issue any and all of said Letters Patent, when granted, to said Sanofi-Synthelabo, as the assignee of my entire right, title and interest in and to the same, for the sole use and behalf of said Sanofi-Synthelabo, its successors and assigns.

DN IVD 1118/DM

FURTHER, we agree that we will communicate to said Sanofi-Synthelabo, or its representatives, any facts known to me respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all patent applications with respect thereto, including divisional, continuation, substitution, renewal and reissue applications, execute all assignment papers to cause any and all of said Letters Patent to be issued to said Sanofi-Synthelabo, make all rightful oaths and generally do everything possible to aid said Sanofi-Synthelabo, its successors and assigns, to obtain and enforce proper protection for said invention in the United States and its territorial possessions and in any and all foreign countries.


IN TESTIMONY WHEREOF, we have hereunto set our hands on the dates indicated below:



1) DUCOUX Jean-Philippe

Date: 20/06/2001

2) EMONDS-ALT Xavier

Date: 20/06/2001

3) GUEULE Patrick

Date: 20/06/2001

4) PROIETTO Vincenzo

Date: 20 06 2001